Pharma BD Deal Intelligence
Vertex paid $245 million upfront (up to $1 billion with milestones) for Exonics' SingleCut CRISPR platform to chase Duchenne and myotonic dystrophy type 1, doubling down alongside an expanded CRISPR Therapeutics pact, though the whole bet remains preclinical.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Vertex's $420M+ preclinical play combines Exonics' SingleCut CRISPR with expanded CRISPR Therapeutics collaboration to establish a DMD/DM1 gene-editing…
Nonprofit CureDuchenne is encouraged to see gene editing for Duchenne advance through Vertex's acquisition of Exonics Therapeutics, validating the gene editing…
The transactions reflect optimistic sentiment around combining complementary IP and expertise to address DMD/DM1, with Sarepta's controversial 2016 Exondys…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Vertex acquired Exonics Therapeutics for $245M upfront plus up to $755M in milestones (~$1B total). Concurrently expanded its collaboration with CRISPR Therapeutics on DMD/DM1 with a $175M upfront and $25M equity investment. Adds CRISPR gene editing platform for Duchenne and myotonic dystrophy.
Myotonic dystrophy type 1 (DM1) is an autosomal-dominant disease caused by a CTG repeat expansion in the DMPK gene, producing toxic RNA that sequesters splicing factors. Patients experience myotonia, progressive muscle weakness, cardiac conduction defects, and cognitive impairment. There are no approved therapies that modify the disease course.
DM1 remains a high-unmet-need orphan with no approved disease-modifying therapy. Active programs at the time of the Vertex-Exonics deal included AMO Pharma's tideglusib (Phase 2/3), Ionis/Biogen's antisense oligonucleotide IONIS-DMPK-2.5Rx (development paused after Phase 1/2), Avidity Biosciences' AOC 1001 (delpacibart etedesiran, antibody-oligonucleotide conjugate, later FORTITUDE-DM1 trial), and academic CRISPR programs targeting the CUG repeat. Vertex's combined Exonics buy plus expanded CRISPR Therapeutics collaboration brought SingleCut Cas9 capability against the toxic repeat. The deal was preclinical, with Vertex projecting Q3 2019 close.
Duchenne muscular dystrophy is a fatal X-linked genetic disease caused by mutations in the dystrophin gene, leading to progressive muscle degeneration and loss of ambulation in childhood, with most patients dying in their 20s or 30s from respiratory or cardiac failure. Approved exon-skipping antisense oligonucleotides (e.g., Sarepta's Exondys 51) only address subsets of mutations and produce limited dystrophin restoration; gene editing aims to permanently repair the defective gene.
DMD has become a battleground for genetic medicine. Sarepta Therapeutics dominates the approved-therapy landscape with exon-skipping ASOs (Exondys 51/eteplirsen approved 2016, Vyondys 53/golodirsen 2019, Amondys 45/casimersen 2021) and microdystrophin gene therapy Elevidys (delandistrogene moxeparvovec, approved 2023). Pfizer pursued mini-dystrophin gene therapy (fordadistrogene movaparvovec, ultimately discontinued in 2024 after Phase 3 failure) following its 2016 Bamboo Therapeutics buy. Solid Biosciences and Genethon have advanced AAV gene therapy programs; PepGen and Wave Life Sciences are advancing next-generation oligonucleotides. Vertex's $245M upfront / $1B-biobucks Exonics acquisition combined with the simultaneously expanded $175M upfront CRISPR Therapeutics collaboration was a preclinical bet on SingleCut CRISPR/Cas9 — the technology demonstrated dystrophin restoration in canine and porcine DMD models from Eric Olson's UT Southwestern lab. The deal positioned Vertex to compete with Sarepta's approved exon-skippers and AAV-microdystrophin players with a one-time gene-editing curative; CureDuchenne CEO Debra Miller publicly endorsed Vertex's track record with rare disease.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated / Exonics Therapeutics (this deal) | 2019 | $1.0B | — |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Vertex Pharmaceuticals Incorporated / Semma Therapeutics Inc. | 2019 | $950M | 86 |
| Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc. | 2017 | $250M | 85 |
| Vertex Pharmaceuticals Incorporated / CRISPR Therapeutics AG | 2015 | $2.6B | 85 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Vertex Pharmaceuticals Incorporated / Crinetics Pharmaceuticals, Inc. | 2026 | $10.0B | 68 |
← Browse all deals · How we score deals
More: 2019 deals · Vertex Pharmaceuticals Incorporated deals · Neurology deals